Anna Aparicio

Biochemistry, Genetics and Molecular Biology · Life Sciences

9h-index1.3kcitations41works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(32), Prostate Cancer Treatment and Research(18), Computational Drug Discovery Methods(8), Advanced Breast Cancer Therapies(6), HER2/EGFR in Cancer Research(5)

Publications41 total

Supplementary Tables 1-7 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 3 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Methods from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 1 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 2 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 2 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Methods from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 4 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Tables 1-7 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 4 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Data from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 5 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 5 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Data from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 1 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 3 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
eLife·2019· 7 citedOpen Access
Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft
Bioorganic & Medicinal Chemistry Letters·2018· 9 citedOpen Access
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927
ACS Medicinal Chemistry Letters·2018· 74 citedOpen Access
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer
Journal of Medicinal Chemistry·2018· 37 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

John Sensintaffar(33), Beatrice Darimont(33), James D. Joseph(32), Peter J. Rix(32), Jeffrey H. Hager(31), Céline Bonnefous(28), Richard A. Heyman(27), Eric D. Bischoff(25), Kate Grillot(22), Nicola J. Clegg(18), Michael E. Jung(18), Charles L. Sawyers(18), Gang Shao(18), John Wongvipat(17), Chris Tran(17), Samedy Ouk(17), Yu Chen(17), Steven Dorow(17), Guangbin Yang(17), Teresa Wasielewska(17)